Market Overview

Omeros Submits NDA for OMS302, Wedbush Says Approval Could be 'Catalyst' for Stock

Related OMER
30 Stocks Moving In Tuesday's Mid-Day Session
Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use
FDA OKs pediatric use for Omeros' Omidria; shares ahead 10% premarket (Seeking Alpha)

Shares of Omeros's (NASDAQ: OMER) traded up as much as 6 percent Thursday morning after the company's announcement of an NDA submission for its intraocular lens replacement surgery treatment OMS302.

The stock charged to a session high of $6.19 (up 15 percent) heading into the last hour of the morning session following comments from Wedbush analyst Liana Moussatos.

She anticipates a 90 percent probability of the FDA accepting the filing for review by late September of this year, with 10-15 percent potential upside in this instance.

Moussatos estimates an 80 percent probability of the NDA being approved by the FDA in mid-2014 with potential upside of 20-40 percent if the approval is made.

Citing peak annual sales for OMS302 of about $479 million and potential partnerships and pipeline progress during the remainder of 2013, Moussatos reiterated an Outperform rating and $18 price target on OMER.

Latest Ratings for OMER

Nov 2017H.C. WainwrightInitiates Coverage OnBuy
Nov 2017Cowen & Co.DowngradesOutperformMarket Perform
May 2017Cantor FitzgeraldDowngradesBuyNeutral

View More Analyst Ratings for OMER
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings Movers


Related Articles (OMER)

View Comments and Join the Discussion!

Partner Center